Pluri (PLUR) Total Current Liabilities (2011 - 2025)
Pluri (PLUR) posted quarterly Total Current Liabilities of $32.3 million for Q4 2025, up 628.51% year-over-year from $4.4 million in Q4 2024, and up 0.58% quarter-over-quarter from $32.2 million in Q3 2025.
Pluri (PLUR) Total Current Liabilities (2011 - 2025) Analysis & Trends
Pluri (PLUR) has reported Total Current Liabilities for 15 consecutive years, with $32.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Current Liabilities rose 628.51% year-over-year to $32.3 million; the TTM figure through Dec 2025 stood at $32.3 million (up 628.51% YoY), while the FY2025 annual figure was $32.3 million, up 625.82% from the prior year.
- Total Current Liabilities rose to $32.3 million in Q4 2025 per PLUR's latest filing, from $32.2 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $32.3 million in Q4 2025 and bottomed at $4.3 million in Q3 2023.
- Historically, Total Current Liabilities has averaged $10.3 million across 5 years, with a median of $5.7 million in 2023.
- Annual changes were most pronounced in 2022 — Total Current Liabilities slumped 51.59% — and 2025, when it jumped 628.51%.
- Pluri's Total Current Liabilities stood at $9.6 million in 2021, then tumbled by 44.93% to $5.3 million in 2022, then retreated by 14.27% to $4.5 million in 2023, then dropped by 1.99% to $4.4 million in 2024, then surged by 628.51% to $32.3 million in 2025.
- Business Quant data shows PLUR's Total Current Liabilities at $32.3 million in Q4 2025, $32.2 million in Q3 2025, and $32.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Pluri | 16.11 Mn | 3.63 Mn | 86,000.00 | 32.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 32.35 Mn |
| Sep 30, 2025 | 32.16 Mn |
| Jun 30, 2025 | 32.33 Mn |
| Mar 31, 2025 | 5.71 Mn |
| Dec 31, 2024 | 4.44 Mn |
| Sep 30, 2024 | 4.58 Mn |
| Jun 30, 2024 | 4.45 Mn |
| Mar 31, 2024 | 4.53 Mn |
| Dec 31, 2023 | 4.53 Mn |
| Sep 30, 2023 | 4.32 Mn |
| Jun 30, 2023 | 5.62 Mn |
| Mar 31, 2023 | 5.38 Mn |
| Dec 31, 2022 | 5.28 Mn |
| Sep 30, 2022 | 5.02 Mn |
| Jun 30, 2022 | 6.83 Mn |
| Mar 31, 2022 | 7.82 Mn |
| Dec 31, 2021 | 9.60 Mn |
| Sep 30, 2021 | 10.37 Mn |
| Jun 30, 2021 | 11.52 Mn |
| Mar 31, 2021 | 9.92 Mn |